کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5619565 1406075 2017 29 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Left Atrial Appendage Occlusion for Stroke Prevention
ترجمه فارسی عنوان
پیشگیری از سکته مغزی بستری در سمت چپ
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی
More than 2.3 million adults in the United States have atrial fibrillation (AF), which exposes them to a 5-fold increased risk of stroke. The left atrial appendage (LAA) appears to be the source of thrombus formation in the vast majority of these patients. Anticoagulation significantly reduces the risk of stroke, but often we encounter patients who have absolute or relative contraindication to anticoagulation. Percutaneous LAA exclusion offers an alternative to anticoagulation to decrease the risk of stroke. Three device systems are currently available in the United States. The WATCHMAN® device is the most studied and approved by Food and Drug Administration (FDA) to be used in patients with AF unsuitable for anticoagulation who are at a high risk of stroke. The Amulet® device is currently being used as part of the AMPLATZER® Amulet® LAA Occluder trial, which is a non-inferiority randomized trial comparing the Amulet® to the WATCHMAN® device. The third device in use is the LARIAT®, which is an FDA approved snare and pre-tied stich system. It is used to approximate soft tissue which in this case is the LAA. It is a hybrid system and requires both epicardial and endocardial access. The main obstacle to percutaneous LAA closure is procedural related complications, which can be minimized with optimum operator experience.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Progress in Cardiovascular Diseases - Volume 59, Issue 6, May–June 2017, Pages 626-635
نویسندگان
, ,